Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
CH0012627250
Mon, 21.10.2024
HBM Healthcare Investments AG
Profit of CHF 23 million
NAV up by 1.5 percent and share price up by 1.7 percent
Private as well as public portfolio companies contribute to earnings
Unfavourable currency movements impact performance by almost 5 percent
Successful first half – currency effects impact performance
HBM Healthcare Investments generated a profit of CHF 23 milli [ … ]
Mon, 21.10.2024
HBM Healthcare Investments AG
Profit of CHF 23 million
NAV up by 1.5 percent and share price up by 1.7 percent
Private as well as public portfolio companies contribute to earnings
Unfavourable currency movements impact performance by almost 5 percent
Successful first half – currency effects impact performance
HBM Healthcare Investments generated a profit of CHF 23 milli [ … ]
Tue, 01.10.2024
HBM Healthcare Investments AG
HBM Healthcare Investments achieved a positive performance in the first half of the 2024/2025 financial year. The net asset value per share (NAV) increased by 1.5 per cent to CHF 244.34. The share price rose by 1.7 per cent to CHF 189.40.
Based on the reported NAV, the company expects a half-year profit of around CHF 23 million (previous year: los [ … ]
Fri, 19.07.2024
HBM Healthcare Investments AG
Quarterly profit of CHF 26 million
NAV increases by 1.6 percent and share price rises by 5.9 percent
Private portfolio companies as value drivers
Positive start to the new financial year
HBM Healthcare Investments started the new 2024/2025 financial year with a quarterly profit of CHF 26 million. The net asset value per share (NAV) rose by [ … ]
Tue, 28.05.2024
HBM Healthcare Investments AG
Validation for the pioneering science and innovation of the Swiss biotech company;
Transaction increases NAV per HBM share by CHF 8.70 (+3.5%); expected cash inflow of USD 78 million for HBM Healthcare Investments.
HBM Healthcare Investments (SIX: HBMN) today announced that Yellow Jersey Therapeutics, a portfolio company [ … ]
Tue, 28.05.2024
HBM Healthcare Investments AG
Validation for the pioneering science and innovation of the Swiss biotech company;
Transaction increases NAV per HBM share by CHF 8.70 (+3.5%); expected cash inflow of USD 78 million for HBM Healthcare Investments.
HBM Healthcare Investments (SIX: HBMN) today announced that Yellow Jersey Therapeutics, a portfolio company [ … ]
Wed, 08.05.2024
HBM Healthcare Investments AG
Slight loss of CHF 1 million
Net asset value per share (NAV) 0.3% higher after share buy-backs
Mixed portfolio performance
Unfavourable currency developments reduce annual result by around 2.5%
Portfolio selectively supplemented with investments in two private companies
Board of Directors proposes unchanged par value repayment of CHF 7.50 per [ … ]
Tue, 02.04.2024
HBM Healthcare Investments AG
HBM Healthcare Investments generated a profit of CHF 156 million in the final quarter of the 2023/24 financial year as at the end of March. This largely made up for the loss from the first nine months. The net asset value per share (NAV) rose by 10.3 per cent to CHF 248.10.
Positive currency effects accounted for around two thirds of the quarte [ … ]
Mon, 22.01.2024
HBM Healthcare Investments AG
Quarter under review closes with a loss of CHF 87 million. For the nine-month period, the loss totalled CHF 158 million
Unfavourable currency developments were the decisive factor
Performance is in line with relevant market indices
Unfavourable currency developments drag HBM Healthcare into the red
HBM Healthcare Investments closed the third [ … ]
Wed, 03.01.2024
HBM Healthcare Investments AG
HBM Healthcare Investments closed the 2023 calendar year with a negative performance due to unfavourable currency developments. The net asset value per share (NAV) fell by 8.3 percent to CHF 225.03. The share price declined by 5.4 percent to CHF 182.60. Currency developments had a negative impact of around 9.5 per cent on performance in 2023 (USD - [ … ]